Statins and coenzyme Q10 [9]

Lancet

Volumn 361, Issue 9363, 2003, Pages 1134-1135

  Ellis, C J ^a   Scott, R ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; STATIN; UBIDECARENONE;

ATHEROMATOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME SYNTHESIS; HEART FAILURE; HEART INFARCTION; HUMAN; INTERNET; LETTER; MUSCLE MITOCHONDRION; MYOPATHY; PRIORITY JOURNAL; STROKE; SUPPLEMENTATION;

EID: 0037471797     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12877-2     Document Type: Letter

References (5)

1. Satoh K., Yamato A., Nakai T., Hoshi K., Ichihara K. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br J Pharmacol. 116:1995;1894-1898.
2. Bliznakov E.G., Wilkins D.J. Biochemical and clinical consequences of inhibiting coenzyme Q10 biosynthesis by lipid lowering HMG-CoA reductase inhibitors (statins): a critical overview. Adv Therapy. 15:1998;218-228.
3. Hargreaves I.P., Heales S. Statins and myopathy. Lancet. 359:2002;711-712.
4. The International Coenzyme Q10 Association. Biochemical and potential clinical consequences of inhibiting coenzyme Q10 biosynthesis by HMG-CoA reductase inhibitors: a critical opinion by the International Coenzyme Q10 Association. http://wwwcsi.unian.it/coenzymeQ/thefirst.html (accessed Jan 31, 2003).
5. Ellis C.J., Scott R. Cardiovascular disease and lipid management in New Zealand: progress at last! NZ Med J. 115:2002;197-199.